

Deprescribing PPIs: FAQs answered by SaferMedsNL

Why should I consider deprescribing proton pump inhibitors for some patients?

PPIs can effectively manage a number of gastrointestinal disorders, including gastroesophageal reflux disease (GERD), reflux esophagitis and *Helicobacter pylori*-associated peptic ulcer disease. However, for most indications, PPI use beyond 12 weeks provides little benefit yet increases the risk of adverse events. The Canadian Association of Gastroenterology and Clinical Practice Guidelines recommend deprescribing PPIs at least once per year unless the patient has a long-term indication.

When should a PPI be continued long term?

- Barrett's esophagus
- Severe esophagitis
- Chronic NSAID users with bleeding risk
- Documented history of bleeding GI ulcer

Is long-term use of proton pump inhibitors associated with harm?

Long-term PPI use has been associated with increases in: vitamin B12 deficiency, *C. difficile* infection, community-acquired pneumonia, fractures, renal complications and hypomagnesemia

Whose PPI should be deprescribed?

Check out the <u>evidence-based deprescribing</u> <u>algorithm</u> created by our collaborators at Bruyère Research Institute.



Evidence-based deprescribing algorithm

Note: the algorithm highlights that if there is no known indication, then the patient is a suitable candidate for deprescribing.

How does Newfoundland and Labrador compare with the rest of Canada?

30% of seniors take a PPI for longer than 12 months.



This means Newfoundland and Labrador has the highest prevalence of long-term PPI use in Canada.

What is the best approach to deprescribing PPIs?

There are two equally effective options for PPI deprescribing:

- 1. Reducing the dose, before stopping
- 2. Stopping the PPI and using it as needed (on demand)

H2RAs, antacids or alginates can be used as needed to manage occasional symptoms however there is a higher chance of symptom return with this approach. Talk to your patient and/or caregivers to identify what is most convenient and acceptable to them.

Will symptoms come back when I deprescribe a PPI?

Up to 50%

of patients who have been on long-term PPIs may experience short-term rebound symptoms following abrupt PPI withdrawal. This can be managed.

Note: this is not a return of the original condition and **does not indicate a need for ongoing therapy**. Talk to your patient about preventing and managing short-term rebound symptoms. Educating patients about tapering regimes, providing advice on managing occasional symptoms and emphasizing realistic goals (that symptoms will go away in a few weeks) are important steps to successful deprescribing of PPIs.

Have you seen the SaferMedsNL proton pump inhibitor care plan recommendation?

The proton pump inhibitor care plan recommendation (also called a pharmaceutical opinion) is an evidence-based form to facilitate communication of a recommendation to deprescribe PPIs between a pharmacist and a prescriber. The form can be used by pharmacists to provide prescribers with relevant clinical information to guide a decision about whether a PPI should be continued or deprescribed.



Pharmacists are encouraged to:

- Talk to the patient about their symptoms and PPI use
- Provide educational materials (see links below)
- Complete a PPI care plan recommendation and fax to physician



Prescribers are encouraged to:

- Review clinical information provided through the PPI care plan recommendation
- Advise whether deprescribing is appropriate or not by faxing the form back to the pharmacist
- Talk to the patient if additional information is required

<u>Recent Canadian evidence</u> supports this approach as a quick and effective way of reducing potentially harmful and unnecessary medications.

Looking for more information?

More information about SaferMedsNL can be found on the website <u>SaferMedsNL.ca</u>. Here you will find access to a range of evidence-based resources including:

- The proton pump inhibitor care plan recommendation
- A patient educational brochure on PPI use
- The <u>PPI deprescribing algorithm</u> to help identify which patients would benefit from deprescribing
- The <u>Clinical Practice Guidelines for PPI</u> deprescribing
- Whiteboard educational videos on deprescribing
 PPIs

And much more...

| Patient Information: | | | Prescriber: | | |
|---|---|--|---|---|--|
| Name: | | | Tel # | Fax # | |
| OB: | | | | | |
| MCP: PPI (drug/dose): | | | Pharmacist: | Pharmacist: | |
| | | | Pharmacy: | | |
| - | (drug) | (dose) | Tel # | Fax # | |
| sociation of Gastro ar unless the patien ✓ Chronic NSAID u | enterology and Cl | linical Practice Guid following Indication risk | dellnes recommend de | | |
| ng-term PPI use may b eumonia, fractures, rer | | | | Infection, community-acquired | |
| eprescribing Reco | ommendation (In | ndicate all that appl | y by checking boxes) | | |
| | s been taking a PP | | | | |
| | | | ve an indication for long | | |
| | | ut their current PPI u you before they dep | | icational brochure on PPI deprescribing | |
| deprescribing A. Advise patie B. Decrease PF | ion with our patien (Please circle A, B, Int to use current s Pl to a lower dose _ | or C) supply of PPI only as mg for | ollowing approach to PP needed (on demand) weeks then stop antacid on demand (as | NOTE: Abrupt PPI withdrawal can commonly cause short term 1 rebound symptoms. Options A and B are both strong recommendations for reducing withdrawal symptoms. Alternaties such as H224a, slightetes and antacids may be less effective at preventine withdrawal symptoms. | |
| I will follow up with our patient to monitor outcome of dependence of the second se | | | depreseribing DDI | See back for further details. | |
| harmacist Comment | | | acproconori g 1 1 i | Date: | |
| | | | | | |
| Response (Indicate one by checking bax) | | | Medication: | | |
| C Deprescribe as per Recommendation A | | | Dose: | | |
| Deprescribe as per recommendation B or C and | | | Instructions for Use: | | |
| replace with: (complete details to the right) | | | Quantity: | | |
| Do not discontinue PPI because: | | | Duration: | | |
| | | | Prescriber Signature | | |
| PLEASE RETURN TO PHARMACY | | | Licence #: | | |
| VIA FAX NUMBER ABOVE | | | Date: | | |
| ferences: Abramowitz et a | f. Otolaryngol Head Neo gy, 2017. Available: <u>choc</u> | k.Surg. 2016 10;155(4):547 psingwiselycenede.org/gs | -554, Benmassaoud et al CM | <u>network.ce/patient-handouts</u> AJ 2016 Jun 14;188(9):657-662, Canadian Grady, JAMA Intern Med 2016:1-3, Ferrell et ol. Car | |

Proton pump inhibitor care plan recommendation



Patient educational brochure

What is SaferMedsNL?

SaferMedsNL is a public awareness initiative that brings together patient advocates, community organizations, healthcare professionals, academic researchers and government to improve medication use through deprescribing potentially harmful or unnecessary medications. <u>Click here</u> to find out more.